Loading
A phase 3 trial of Oxaliplatin, Tegafur, gimeracil and oteracil and Capecitabine in Colorectal cancer, run by Peking University Cancer Hospital & Institute, with a status the registry has not verified recently.
SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients is a phase 3 interventional study registered as NCT03448549 by Peking University Cancer Hospital & Institute, with 1191 participants planned, started 2018-01-01 and due to reach its primary completion in 2021-01-01. Interventions recorded: Oxaliplatin, Tegafur，gimeracil and oteracil potassium, Xeloda. Conditions recorded: Colorectal Cancer Stage III, Adjuvant Chemotherapy.
Linked to the drug Tegafur, gimeracil and oteracil because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Tegafur, gimeracil and oteracil (S-1), Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.